Dr. Delion received is Ph.D. from the Univerisity of Reims Champagne-Ardenne, France, in October 2016. He worked on human primary osteoblasts and his subject was to understand what cellular pathways are involved in Cystic Fibrosis-related bone disease. His next goal was to estimate if CFTR modulation, especially by Vertex compounds, could normalize the pathways impacted by the disease. Currently Dr. Delion is a postdoctoral fellow at the University of North Carolina at Chapel Hill. At the Marsico lung institute, he is working on the mucus physicochemical properties change in Cystic fibrosis and the impact of CFTR restoration on those properties.